Smart ring maker Oura plans $2.2 billion US IPO

**Oura's IPO Bid and What's on the Table**

Finnish health-technology company Oura Inc. is moving to go public on US markets, seeking to raise as much as $2.2 billion through an initial public offering. The company filed with the Securities and Exchange Commission and plans to market 50 million shares at a price range of $40 to $44 each. Of those shares, Oura itself will offer 13.5 million, which means the bulk of the offering — 36.5 million shares — will come from existing investors cashing out, including early backers Forerunner Ventures and Lifeline Ventures. At the top of the range, the deal would value the company at a substantial premium to its last known private valuation and represent one of the more significant consumer health-technology listings in recent memory.

The structure of the offering is notable: because the majority of shares are being sold by insiders rather than the company itself, Oura will capture a relatively smaller portion of the gross proceeds. At $44 per share, the company's 13.5 million shares would yield roughly $594 million in fresh capital for corporate purposes, while the remaining $1.6 billion would flow to selling shareholders. This kind of secondary-heavy IPO often signals that early investors see the current moment as an attractive exit window, though it can also raise questions among public-market investors about whether insiders believe the stock is fully valued.

**What Oura Makes and Why It Matters**

Oura has carved out a distinctive position in the crowded wearable-technology market by focusing almost entirely on the finger rather than the wrist. Its smart ring, sold under the Oura Ring brand, tracks a dense array of physiological signals — heart rate and heart rate variability, blood oxygen levels, body temperature, activity, and sleep architecture — and synthesizes them into readiness and wellness scores delivered through a companion smartphone app. The device has built a devoted following among biohackers, elite athletes, and health-conscious consumers who prefer the ring's discreet form factor and its emphasis on recovery and longitudinal health tracking over the real-time notifications and fitness gamification that dominate smartwatch products from Apple and Samsung.

The company was founded in Finland and has steadily expanded its subscriber base through a model that pairs hardware sales with a monthly software subscription, a structure that gives Oura recurring revenue on top of device sales and makes its financials look more like a software business than a pure consumer-electronics manufacturer. That hybrid model has been central to its pitch to investors, as subscription revenue is generally valued at higher multiples than one-time hardware transactions. The ring also gained significant mainstream visibility when it was worn by high-profile athletes and, during the COVID-19 pandemic, was piloted in research programs studying early illness detection through biometric signals — a period that helped validate the device's clinical credibility beyond the wellness market.

**The Competitive Landscape and Timing**

Oura's IPO arrives at a moment when the broader wearable-health market is becoming significantly more contested. Samsung launched its own Galaxy Ring in 2024, bringing the resources and distribution of one of the world's largest consumer-electronics companies directly into Oura's core product category. Apple, though not yet in the ring market, continues to deepen the health capabilities of the Apple Watch, and a range of smaller competitors — including Ultrahuman and RingConn — are targeting budget-conscious consumers with lower-cost alternatives. For Oura, going public now may reflect a strategic judgment that raising capital and establishing a public market profile is essential to sustaining its brand and technology lead before larger rivals consolidate the category.

The IPO market itself has shown renewed receptivity to technology listings after a prolonged drought following the 2021-2022 reset in growth-stock valuations. A successful Oura offering at the top of its range would be read as a signal that public investors are again willing to pay growth premiums for consumer health platforms with subscription economics, potentially opening the door for other venture-backed health and wellness companies watching the filing closely.

**Investor Implications and Open Questions**

The participation of Forerunner Ventures and Lifeline Ventures as selling shareholders places two prominent names in the spotlight. Forerunner, led by Kirsten Green, built its reputation backing consumer brands — including Warby Parker and Glossier — and has been an Oura investor as the company scaled internationally. Lifeline Ventures is a Helsinki-based early-stage fund that has backed Oura from its earliest days, making the IPO a significant liquidity event for the Finnish venture ecosystem.

For prospective public investors, the key questions will center on subscriber growth rates and churn, the unit economics of the hardware business as competition forces potential price pressure, and how aggressively Oura can expand into adjacent health markets — including, potentially, FDA-cleared medical applications — that could substantially widen its addressable market. The company's ability to maintain differentiation through proprietary algorithms and sensor accuracy, rather than competing on hardware specifications alone, will likely be the central narrative in its roadshow conversations with institutional investors. Whether the $40-to-$44 price range prices in sufficient upside to attract long-term holders, rather than traders looking for a first-day pop, may ultimately determine how the offering is remembered.